Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Advisory - Multiple unauthorized health products sold at Sunrise Lee Chinese Herbs Centre in Calgary, Alberta, may pose serious health risks


OTTAWA, April 5, 2019 /CNW/ - Health Canada is advising consumers that several health products sold at Sunrise Lee Chinese Herbs Centre (999 36th Street NE) in Calgary, Alberta, are unauthorized and may pose serious health risks. The products include sexual enhancement capsules, cold and flu tablets and creams for a variety of skin conditions.

Compound Diclofenac Sodium and Chlorphenamine Maleate Tablets (CNW Group/Health Canada)

They are labelled to contain prescription or banned drugs (see below). Most of the unauthorized health products are packaged and labelled in Chinese characters. As a result, information about ingredients, usage, dosage and side effects may not be understood by all consumers. Prescription drugs should be taken only under the advice and supervision of a healthcare professional because they are used to treat specific diseases and may cause serious side effects.

Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, effectiveness and quality and may pose serious health risks. They may contain ingredients, additives or contaminated ingredients not listed on the label. In addition, they may lack the active ingredients Canadians would expect them to contain to help maintain and improve their health or they may contain ingredients that could interact with other medications and foods. For all of these reasons, unauthorized health products could cause serious health effects. Selling unauthorized health products in Canada is illegal.

Who is affected

Affected products

 

Product

Risk

Compound Diclofenac Sodium and Chlorphenamine Maleate Tablets

Labelled in English to contain diclofenac sodium, a prescription drug, and chlorphenamine maleate, a non-prescription drug

Dexamethasone Acetate Cream

Labelled in Chinese to contain dexamethasone acetate, a prescription drug

Fluocinonide Cream

Labelled in English to contain fluocinonide, a prescription drug

Fluocinonide Cream 0.025%

Labelled in English to contain fluocinonide, a prescription drug

I-Ching-Sung Diacetyldiphenolisatin 5 mg Tablets

Labelled in English to contain diacetyldiphenolisatin, a banned drug

Yansuan Jinmeisu Yangao

Labelled in Chinese to contain chlortetracycline HCl, a prescription drug not approved in Canada for human use

Yohimbe XV

Labelled in English to contain yohimbe bark extract, a prescription drug

 

What consumers should do

What Health Canada is doing

Health Canada removed the products from the retail location. Should additional safety concerns be identified, Health Canada will take appropriate action and inform Canadians as necessary.

Background

These health products were labelled to contain undeclared drug or banned drugs, which may pose serious health risks.

Chlorphenamine maleate is a non-prescription antihistamine drug. Side effects include drowsiness, dizziness, confusion and blurred vision.

Chlortetracycline Hydrochloride (HCl) is a prescription drug for veterinary use that is not approved for human use in Canada. It has not been reviewed by Health Canada for safety, effectiveness and quality for use in humans. It belongs to a class of drugs known as tetracycline-type antibiotics.

Dexamethasone is a prescription corticosteroid drug used to treat various inflammatory conditions. Dexamethasone has not been approved for use in creams in Canada. Dexamethasone can be absorbed through the skin, which may cause side effects throughout the body, especially when used over a large surface area and for a long time. This risk is greater in children, who may absorb proportionally larger amounts and be more susceptible to systemic toxicity. Side effects could include high blood pressure, high blood sugar, blurred vision, uneven heartbeats, weakness, swelling, and thinning of the skin. Dexamethasone is generally not recommended for use during pregnancy.

Diacetyldiphenolisatin, also known as oxyphenisatin acetate, is banned in Canada and elsewhere because of the risk of serious liver damage. It had been used previously as a laxative drug for treating constipation.

Diclofenac for oral consumption is a prescription drug used to relieve the pain and swelling caused by arthritis. It increases the risk of serious heart-related events such as heart attack and stroke, high blood pressure, stomach or intestinal bleeding or ulcers, kidney problems, serious liver disease, and bleeding or clotting problems. It should not be used in patients who have severe uncontrolled hypertension, a history of asthma or allergic-type reactions after taking acetylsalicylic acid (ASA) or non-steroidal anti-inflammatories (NSAIDs) including diclofenac, women in the first and third trimesters of pregnancy, and those who are breastfeeding.

Fluocinonide cream is a prescription corticosteroid drug used to treat inflammation and itching caused by skin conditions such as allergic reactions and eczema. It is a relatively strong corticosteroid cream. It can be absorbed through the skin, which may cause side effects throughout the body, especially when used over a large surface and for a long time. This risk is greater in children, who may absorb proportionally larger amounts and be more susceptible to systemic toxicity. Side effects could include high blood pressure, high blood sugar, blurred vision, uneven heartbeats, weakness, swelling, or thinning of the skin. It is generally not recommended during pregnancy.

Yohimbine is a prescription drug and should be used only under the supervision of a health care professional. Yohimbine is derived from yohimbe, a bark extract. The use of yohimbine or yohimbe may result in serious adverse reactions, particularly in people with high blood pressure, or heart, kidney or liver disease. Side effects include increased blood pressure and heart rate, anxiety, dizziness, tremors, headache, nausea and sleep disorders. It should not be used by children, or pregnant or nursing women.

Également disponible en français

 

Dexamethasone Acetate Cream (CNW Group/Health Canada)

Fluocinonide Cream (CNW Group/Health Canada)

Fluocinonide Cream 0.025% (CNW Group/Health Canada)

I-Ching-Sung Diacetyldiphenolisatin 5 mg Tablets (CNW Group/Health Canada)

Yansuan Jinmeisu Yangao (CNW Group/Health Canada)

Yohimbe XV (bottle) (CNW Group/Health Canada)

Yohimbe XV (individual capsule) (CNW Group/Health Canada)

SOURCE Health Canada


These press releases may also interest you

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

at 11:55
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 11:40
The "Musculoskeletal Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the...

at 11:30
The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024....



News published on and distributed by: